Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura

International Journal of Hematology

Volumn 89, Issue 3, 2009, Pages 305-309

  Goto, Shoko ^a   Goto, Hiroaki ^b   Tanoshima, Reo ^a   Kato, Hiromi ^a   Takahashi, Hiroyuki ^a   Sekiguchi, Osamu ^a   Kai, Sumio ^a  

^a SAISEIKAI YOKOHAMASHI NANBU HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Child; Chronic ITP; Human anti chimeric antibody; Rituximab; Serum sickness

Indexed keywords

CHIMERIC ANTIBODY; HYDROCORTISONE SODIUM SUCCINATE; HYDROXYZINE; IMMUNOGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RITUXIMAB; ANTIIDIOTYPIC ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ANAMNESIS; ARTHRALGIA; ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLAMMATION; MACULOPAPULAR RASH; MALAISE; RELAPSE; REMISSION; SERUM SICKNESS; SIDE EFFECT; BLOOD; CASE REPORT; IMMUNOLOGY; IMMUNOTHERAPY; MALE;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CHILD; CHRONIC DISEASE; HUMANS; IMMUNOTHERAPY; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECOMBINANT FUSION PROTEINS;

EID: 67649227736     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0269-6     Document Type: Article

References (25)

1. W Stevens H Koene JJ Zwaginga G Vreugdenhil 2006 Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights Neth J Med 64 356 63
2. RY Tamminga MC Bruin 2006 Rituximab treatment for symptomatic chronic ITP Pediatr Blood Cancer 47 714 6 10.1002/pbc.20967 (Pubitemid 44360038)
3. FJ Peñalver V Jiménez-Yuste M Almagro 2006 Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients Ann Hematol 85 400 6 10.1007/s00277-006-0123-3 (Pubitemid 44283105)
4. S Panzer 2008 New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review Vox Sang 94 1 5
5. MN Saleh J Gutheil M Moore 2000 A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia Semin Oncol 27 99 103
6. R Stasi A Pagano E Stipa S Amadori 2001 Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 98 952 7 10.1182/blood.V98.4.952
7. R Stasi E Stipa V Forte P Meo S Amadori 2002 Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura Blood 99 3872 3 10.1182/blood-2002-02-0392 (Pubitemid 34534570)
8. AA Giagounidis J Anhuf P Schneider 2002 Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study Eur J Haematol 69 95 100 10.1034/j.1600-0609.2002.02686.x (Pubitemid 35178108)
9. P Braendstrup OW Bjerrum OJ Nielsen 2005 Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura Am J Hematol 78 275 80 10.1002/ajh.20276 (Pubitemid 40471119)
10. Neunert CE, Bright BC, Buchanan GR. Severe chronic refractory immune thrombocytopenic purpura during childhood: a survey of physician management. Pediatr Blood Cancer. 2008; 51:513-6.
11. J Wang JM Wiley R Luddy J Greenberg MA Feuerstein JB Bussel 2005 Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment J Pediatr 146 217 21 10.1016/j.jpeds.2004.09.004 (Pubitemid 40202812)
12. CM Bennet ZR Rogers DD Kinnamon 2006 Prospective phase I/II study of rituximab in children and adolescent chronic immune thrombocytopenic purpura Blood 107 2639 42 10.1182/blood-2005-08-3518
13. DJ Todd SM Helfgott 2007 Serum sickness following treatment with rituximab J Rheumatol 34 430 3
14. JC Edwards L Szczepanski J Szczepanski 2004 Effect of B-cell targeted therapy with rituximab in patients with rhenmatoid arthritis N Engl J Med 350 2572 81 10.1056/NEJMoa032534 (Pubitemid 38758544)
15. GR Buchanan L Adix 2002 Grading of hemorrhage in children with idiopathic thrombocytopenic purpura J Pediatr 141 683 8 10.1067/mpd.2002.128547 (Pubitemid 35292768)
16. J Pijpe GW van Imhoff FK Spijkervet 2005 Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study Arthritis Rheum 52 2740 50 10.1002/art.21260 (Pubitemid 41369102)
17. CA D'Arcy M Mannik 2001 Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab) Arthritis Rheum 44 1717 8 10.1002/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C (Pubitemid 32642238)
18. Y Herishanu 2002 Rituximab-induced serum sickness Am J Hematol 70 329 10.1002/ajh.10127
19. B Hellerstedt A Ahmed 2003 Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment Ann Oncol 14 1792 10.1093/annonc/mdg488
20. M Catuogno S Rezai R Priori L Magrini G Valesini 2005 Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia Rheumatology 44 406 10.1093/rheumatology/keh470 (Pubitemid 40361306)
21. JE Gottenberg L Guillevin O Lambotte 2005 Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases Ann Rheum Dis 64 913 20 10.1136/ard.2004.029694 (Pubitemid 40733918)
22. CS Portlock OA O'Connor DJ Straus 2006 Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation? Leuk Lymphoma 47 1260 4 10.1080/10428190600565354 (Pubitemid 44269632)
23. R Seror C Sordet L Guillevin 2007 Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome Ann Rheum Dis 66 351 7 10.1136/ard.2006.057919 (Pubitemid 46579637)
24. RE Schutgens 2006 Rituximab-induced serum sickness Br J Haematol 135 147 10.1111/j.1365-2141.2006.06214.x (Pubitemid 44401609)
25. NA DeMonaco SA Jacobs 2007 Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan Clin Nucl Med 32 933 4